The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
198 reports and counting
Varda Raises $251M Series D for Space-Based Pharmaceutical Processing
Varda Space Industries raised a $251 million Series D led by Lux Capital and Natural Capital to scale space-based pharmaceutical processing.
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Altis Labs Raises $25M Series A for AI Clinical-Trial Endpoints
Altis Labs raised a $25 million Series A co-led by OrbiMed and Qiming Venture Partners USA to expand AI endpoints for oncology clinical trials.
Graph AI Raises $13.3M Series A for Patient-Safety Automation
Graph AI raised a $13.3 million Series A led by Insight Partners to expand its AI-native pharmacovigilance platform in the US and Europe.
Cloverleaf Bio Raises $33M Seed Round for RNA Cancer Therapeutics
Cloverleaf Bio closed an oversubscribed $33 million seed round to advance engineered tRNA therapeutics for liver and colorectal cancers.
SpyGlass Pharma Opens New Headquarters in Irvine
SpyGlass Pharma opened a 33,000-square-foot headquarters in Irvine, California, on August 27, 2026, moving from its former facility in Aliso Viejo as it prepares for its first product launch.
The Emmes Group Appoints Rama Kondru Chief Executive Officer
The Emmes Group’s Board appointed Rama Kondru, most recently CEO of its Veridix AI, technology, and data sciences business, as Chief Executive Officer.
Remepy Raises $36M Series A to Advance Hybrid Drug Pipeline
Remepy raised a $36 million Series A led by O.G. Venture Partners and M Ventures to expand its Hybrid Drug pipeline and fund Phase III development of Hybridopa for Parkinson’s disease.
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.